CorMedix (CRMD) COO Elizabeth Hurlburt gains 36,006 shares from PSU achievement

Rhea-AI Filing Summary

CorMedix Inc. Chief Operating Officer Elizabeth Hurlburt reported an equity-related award linked to performance stock units. On 02/04/2026, she acquired 36,006 shares of CorMedix common stock at a reported price of $0.00, increasing her beneficial ownership to 278,539 directly held shares.

The filing explains this reflects achievement of performance stock units granted on January 2, 2025, after the Compensation Committee determined that performance conditions for the first of three performance periods were met. These units remain subject to additional time-based vesting requirements for Hurlburt.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hurlburt Elizabeth

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	36,006	$0.00	--

Holdings After Transaction: Common Stock — 278,539 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hurlburt Elizabeth

(Last) (First) (Middle)

C/O CORMEDIX INC.,

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		A		36,006	A	$0.00(1)	278,539	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the achievement of performance stock units ("PSUs") upon the determination of the Compensation Committee of the Issuer that the performance conditions specific to the first of three performance periods were met with respect to the PSUs granted to the Reporting Person on January 2, 2025. The PSUs are subject to vesting upon satisfaction of time-based vesting conditions by the Reporting Person.

	/s/ Beth Zelnick Kaufman, attorney-in-fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CorMedix (CRMD) report for Elizabeth Hurlburt?

CorMedix reported that COO Elizabeth Hurlburt acquired 36,006 common shares. The 02/04/2026 Form 4 shows her receiving these shares at a reported price of $0.00, tied to performance stock units whose first performance period conditions were met.

How many CorMedix (CRMD) shares does Elizabeth Hurlburt now beneficially own?

After the reported transaction, Hurlburt beneficially owns 278,539 common shares directly. This total reflects the addition of 36,006 shares associated with achieved performance stock units, as disclosed in the Form 4 insider filing dated 02/04/2026.

What triggered the 36,006-share award to CorMedix COO Elizabeth Hurlburt?

The award was triggered by achievement of performance stock units. CorMedix’s Compensation Committee determined that performance conditions for the first of three performance periods were met for PSUs granted on January 2, 2025, resulting in 36,006 shares being credited.

Are the performance stock units for CorMedix (CRMD) fully vested for Elizabeth Hurlburt?

No, the performance stock units remain subject to time-based vesting. The Form 4 notes that, although the first performance period conditions were achieved, the PSUs still require satisfaction of time-based vesting conditions by Hurlburt before they fully vest.

What role does Elizabeth Hurlburt hold at CorMedix (CRMD) in this Form 4?

Elizabeth Hurlburt is identified as CorMedix’s Chief Operating Officer. The Form 4 lists her as an officer, not a director or 10% owner, and reports her equity acquisition as a direct ownership position in the company’s common stock.

What transaction code appears in the CorMedix (CRMD) Form 4 for this award?

The Form 4 lists transaction code “A” for the reported acquisition. This code applies to the 36,006 CorMedix common shares credited in connection with achieved performance stock units on the 02/04/2026 transaction date.